Key Advisors

Dr. Bruce Conklin

Dr. Bruce R. Conklin utilizes bioinformatics, receptor engineering, and stem cell biology to understand basic pharmacological responses. He currently serves as senior investigator at the Gladstone Institute of Cardiovascular Disease, and professor of Medical Genetics at the University of California, San Francisco. Dr. Conklin served as the founding director of the Gladstone Genomics Core and the founding director of the Gladstone Stem Cell Core. He was previously associate director of the General Clinical Research Center at San Francisco General Hospital. Dr. Conklin received an A.B. degree in public health from the University of California, Berkeley. He received his M.D. from Case Western Reserve University, completed his internal medicine residency at Johns Hopkins, and his postdoctoral training in molecular pharmacology at UCSF.

Robert Millman

Robert Millman brings experience in creating and managing intellectual property and patent estates for biotechnology and drug discovery and development companies. Most recently, he was the Chief IP Counsel for Alnylam Pharmaceuticals Inc. where he developed the leading intellectual property portfolio in RNAi therapeutics. Prior to Alnylam, for three years he served as the Chief IP Counsel at Infinity Pharmaceuticals, Inc. a company focused on small molecule discovery. From 1999 to 2002, Mr. Millman was Chief IP Counsel at Celera Genomics, where he development and implemented an IP protection plan during the race to sequence the human genome. In addition, Mr. Millman previously served at Millennium Pharmaceuticals, Inc., Morrison and Foerster LLP, and Sterne, Kessler Goldstein and Fox, LLP. Mr. Millman received his J.D. degree from the Washington College of Law at The American University, an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside.